Ann: First Patient Treated in Phase 2 GvHD Trial, page-41

"I still think it matters what the breakdown of treatment to control arm is - is it 30 and 30 or 40 and 20?"

This has been addressed by the company - it is 30 and 30.

"but is a lot of potentially different locations - which can sometimes introduce other variables."

I'm not aware of a GvHD trial where the number of locations used has been a consideration in approving or rejecting a clinical product. IMO it is an accepted reality that patients have to be recruited from a wide range of different locations as the condition is so rare.

"I will be very pleasantly surprised...if they actually complete recruitment by the end of the year"

Me too. Consider that recruitment is expected to complete this calendar year, but results are not expected until H2 2025...despite the endpoints being at 100 days (just over 3 months). Either they're planning to over-deliver with on-time recruitment and early results, or miss the recruitment time-frame but meet the results guidance. A bit of a bet each-way IMO.